Disease · MONDO_0002869
heart valve disorder
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. heart valve disorder. Diseases, record MONDO_0002869. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002869
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
cardial valve disease, cardial valve disease or disorder, disease of cardial valve, disease or disorder of cardial valve, disorder of cardial valve, disorder of heart valve, heart valve disease, valvular heart disease, valvular heart disorder
- Open Targets
Drugs15
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| APIXABAN | CHEMBL231779 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HETASTARCH | CHEMBL2108448 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| KETOROLAC | CHEMBL469 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LIDOCAINE | CHEMBL79 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TELITACICEPT | CHEMBL5095293 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PROPOFOL | CHEMBL526 | Small molecule | Phase 1 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| EPOPROSTENOL | CHEMBL1139 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ISOFLURANE | CHEMBL1256 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NITROGLYCERIN | CHEMBL730 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 15
See all 15 drugsTargets44
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GABRA1 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2559 | Drugs and targets |
| GABRB1 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2560 | Drugs and targets |
| GABRB2 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2561 | Drugs and targets |
| GABRB3 | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2562 | Drugs and targets |
| GABRD | GABA-A receptor; anion channel | 3 | GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2563 | Drugs and targets |
1 to 10 of 44
See all 44 targetsTrials10
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00537290 | A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome | Phase 2 | 19 | 2017-10-31 | Antiphospholipid Syndrome | RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05687448 | DIrect Oral Anticoagulation and Bioprothesis Aortic Valve | Phase 3 | 1,500 | Aortic Valve Disease | APIXABAN | Its record names the disease | ClinicalTrials.gov | |
| NCT05151796 | Continuation of Aspirin Before Isolated Heart Valve Surgery | 500 | Isolated Heart Valve Surgery | ASPIRIN | Its record names the disease | ClinicalTrials.gov | ||
| NCT04594629 | PGI2 Versus Nitroglycerine for Management of Pulmonary Hypertension After Valve Surgeries | Phase 1 | 120 | Pulmonary Hypertension | EPOPROSTENOL, NITROGLYCERIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05223361 | Cardiopulmonary Bypass Prime Solution in Patients Undergoing Heart Valve Surgery | Phase 3 | 120 | Heart Valve Diseases | HETASTARCH | Its record names the disease | ClinicalTrials.gov | |
| NCT01571791 | Perioperative Ketorolac-lidocaine in the Patients With Valvular Heart Diseases During Cesarean Delivery | Phase 2 | 90 | Valve Heart Disease, Elective Cesarean Delivery | KETOROLAC, LIDOCAINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05695287 | The Effects of Sevoflurane, Isoflurane and Propofol During Cardiac Surgery | Phase 1 | 89 | Coronary Artery Disease, Mitral Valve Insufficiency, Aortic Valve Insufficiency | ISOFLURANE, PROPOFOL, SEVOFLURANE | Its record names the disease | ClinicalTrials.gov | |
| NCT04306913 | Outcome of Esmolol Potassium Cardioplegia Compared to Potassium Cardioplegia in Patients With Solitary Valvular Disease; Randomized Controlled Study | Not applicable | 80 | Cardioplegia Solution Adverse Reaction | ESMOLOL | Its record names the disease | ClinicalTrials.gov | |
| NCT02400879 | Remifentanil Anesthesia and Postoperative BIS in Cardiac Surgery | Not applicable | 38 | Cardiovascular Disease | PROPOFOL, REMIFENTANIL | Its record names the disease | ClinicalTrials.gov | |
| NCT05078710 | Telitacicept in Primary APS Patients | Phase 2 | 20 | Anti Phospholipid Syndrome | TELITACICEPT | Open Targets' reading of its record | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002869
GET https://conductscience.org/api/diseases/v1/MONDO_0002869/targets?page=2